HLA-A and acute myeloid leukemia: In a phase I trial, Brayer and colleagues [11] showed a mean DFS of 244 days (range, 30–445 days) and a mean OS of 608 days (range, 201–1071 days) in 14 AML patients in CR1 and CR2 treated with an oligopeptide vaccine composed of a mixture of peptides including both class I (restricted to HLA-A*0201) and class II epitopes.